OPINION: A massive bias in medical studies toward men of European origin means that genetic variants in understudied populations don’t get the focus they deserve
Polygenic risk scores — a patient’s chance, based on tiny DNA variants, of developing cardiovascular disease, breast cancer and more — are coming to clinics. But there are kinks to iron out and accuracy remains an issue.
A scientist whose work was key to identifying, studying and finding treatments for this life-threatening virus discusses the scientific journey and challenges that persist
The pandemic put the technology, long in development, to the test. Here’s a look at the status of its application to cancer and when it might reach patients.
A handful of animals make a pared-down version of these pathogen-fighting proteins of our immune system. Scientists hope to harness them as treatments for ills from cancer to Covid, for tracking cells in the body, and more.
Some parts of the world are on the path to largely eradicating cervical cancer, but the story is less rosy for other populations, including US Hispanics. Why, and what can be done about it?
When a malignancy or chronic infection sets in, a kind of immune combat fatigue can follow. Finding ways to recharge immune cells can restore their ability to fight deadly diseases, says immunologist John Wherry.
Scientists are finding that microscopic membranous bubbles called extracellular vesicles transmit messages from cells and do big jobs in many areas of biology — plus they might be useful for therapies.
Only about 10 percent of people with breast cancer have links to known gene variants, but another 20 percent have significant family history. Scientists are delving deeper into the genome to find what remains unexplained.
The Nobel laureate and former NIH director talks about how far the field has come, where it should go and why some of the best discoveries in oncology still aren’t reaching patients who need them
